Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8933 USD | +10.82% | +21.87% | +10.28% |
Apr. 25 | Transcript : HOOKIPA Pharma Inc. - Special Call | |
Apr. 25 | HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.28% | 79.76M | |
+25.83% | 653B | |
+27.00% | 556B | |
-6.76% | 354B | |
+20.34% | 331B | |
+3.00% | 296B | |
+13.09% | 233B | |
+5.46% | 201B | |
-9.61% | 193B | |
-6.26% | 144B |
- Stock Market
- Equities
- HOOK Stock
- News HOOKIPA Pharma Inc.
- Hookipa Pharma : Releases Positive Interim Data From Study of Potential HPV+ Cancer Drug